L O Mügge - JoVE Visualize

Showing results (1-10 of 9) with videos related to

Pageof 1

Sort By:

Journal of Cancer Research and Clinical Oncology|February 12, 2009

Current treatment options in dermatofibrosarcoma protuberansDoreen Lemm, L-O Mügge, T Mentzel, et al.

Pneumologie (Stuttgart, Germany)|March 10, 2001

[Effect of surgical positioning and spinal anesthesia on lung function]B Rassler, L O Mügge, S Waurick, et al.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|November 2, 2007

[Cutaneous melanoma]T K Eigentler, L-O Mügge, A Bembenek, et al.

Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000

Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cellsA N Vallejo, L O Mügge, P A Klimiuk, et al.

Leukemia Research|February 20, 2007

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemiaS Scholl, L-O Mügge, O Landt, et al.

Bone Marrow Transplantation|November 9, 2004

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCTS Scholl, L O Mügge, M Charbel Issa, et al.

Bone Marrow Transplantation|January 6, 2004

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donorsC Kasper, H G Sayer, L O Mügge, et al.

Clinical and Experimental Immunology|April 10, 2014

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patientsA Busch, D Zeh, V Janzen, et al.

Leukemia|December 27, 2016

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)J Krönke, F Kuchenbauer, M Kull, et al.

Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:

Pageof 1

Journal of Cancer Research and Clinical Oncology|February 12, 2009

Current treatment options in dermatofibrosarcoma protuberansDoreen Lemm, L-O Mügge, T Mentzel, et al.

Pneumologie (Stuttgart, Germany)|March 10, 2001

[Effect of surgical positioning and spinal anesthesia on lung function]B Rassler, L O Mügge, S Waurick, et al.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|November 2, 2007

[Cutaneous melanoma]T K Eigentler, L-O Mügge, A Bembenek, et al.

Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000

Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cellsA N Vallejo, L O Mügge, P A Klimiuk, et al.

Leukemia Research|February 20, 2007

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemiaS Scholl, L-O Mügge, O Landt, et al.

Bone Marrow Transplantation|November 9, 2004

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCTS Scholl, L O Mügge, M Charbel Issa, et al.

Bone Marrow Transplantation|January 6, 2004

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donorsC Kasper, H G Sayer, L O Mügge, et al.

Clinical and Experimental Immunology|April 10, 2014

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patientsA Busch, D Zeh, V Janzen, et al.

Leukemia|December 27, 2016

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)J Krönke, F Kuchenbauer, M Kull, et al.

Pageof 1